Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.73 |
| ▸ | OPRM1 | P35372 | 13/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 13/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8541761 | 1.00 | HRH3 (0.73) | HRH3OPRM1OPRD1CHRNA7SIGMAR1 | |
| SCHEMBL29691892 | 0.82 | CHRM2 (0.53) | HRH3OPRM1OPRD1CHRNA7SIGMAR1 | |
| SCHEMBL16766368 | 0.82 | CHRM2 (0.53) | HRH3OPRM1OPRD1CHRNA7SIGMAR1 | |
| SCHEMBL19364501 | 0.82 | CHRM2 (0.53) | HRH3OPRM1OPRD1CHRNA7SIGMAR1 | |
| SCHEMBL719296 | 0.82 | CHRM2 (0.53) | HRH3OPRM1OPRD1CHRNA7SIGMAR1 | |
| SCHEMBL707808 | 0.82 | CHRM2 (0.53) | HRH3OPRM1OPRD1CHRNA7SIGMAR1 | |
| Hydrochloric Acid SCHEMBL1633577 | 0.81 | CHRM2 (0.56) | HRH3OPRM1OPRD1SIGMAR1 | |
| SCHEMBL27751179 | 0.80 | HRH3 (0.89) | HRH3OPRM1OPRD1CHRNA7SIGMAR1 | |
| SCHEMBL19013666 | 0.77 | HRH3 (0.76) | HRH3OPRM1OPRD1CHRNA7 | |
| SCHEMBL12902953 | 0.76 | KMT2A (0.51) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004163-A1 | 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-01-06 | — | — | US | disclosed |
| US-20030181447-A1 | 3-(Diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives | BOYD ROBERT E (US) | 2003-09-25 | — | — | US | disclosed |
| US-6552036-B2 | Delta-opioid or mu-opioid receptor modulators; useful analgesics, immunosuppressants, antiinflammatory agents, agents for the treatment of respiratory diseases. | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-04-22 | — | — | US | disclosed |
| EP-1263758-A2 | 3-(DIARYLMETHYLENE)-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020115662-A1 | 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives | BOYD ROBERT E (US) | 2002-08-22 | — | — | US | disclosed |
| WO-2001066543-A2 | 3-(DIARYLMETHYLENE)-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
| WO-2000004017-A1 | AZABICYCLE-SUBSTITUTED PHENYLINDOLE DERIVATIVES AS LIGANDS FOR 5-HT2A RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2000-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004163-A1 | 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives | OPRD1, OPRM1, OPRK1 | HRH3 1065/4885OPRM1 2/4885OPRD1 1/4885 |
| US-20020115662-A1 | 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives | OPRM1, OPRK1, OPRD1 | HRH3 802/4885OPRM1 1/4885OPRD1 3/4885 |
| US-20030181447-A1 | 3-(Diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives | OPRM1, OPRK1, OPRD1 | HRH3 802/4885OPRM1 1/4885OPRD1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.